At Evolv, science is not an afterthought. It is the foundation. The EV1 Peptide™, the first biomimetic GLP-1 designed for oral delivery, emerged from decades of research in molecular biology, expression systems, and peptide engineering.
Behind this innovation are Dr. Cory Henderson and Dr. Kwang-Chul Kwon, Evolv’s scientific co-founders and co-inventors of the EV1 Peptide™. Together, they bring a record of discovery that spans prestigious academic fellowships, award-winning publications, patented technologies, and leadership across multiple biotechnology platforms. Their combined expertise represents one of the strongest scientific pedigrees in the consumer health space today.
Cory Henderson, Ph.D., is a molecular biologist recognized as a National Science Foundation Graduate Research Fellow during his doctoral studies at Penn State University. His research in arbovirus transmission and host–pathogen interactions produced peer-reviewed publications in leading journals including Journal of Virology, PLOS Neglected Tropical Diseases, and G3.
As Co-Founder and CEO of Evolv, Dr. Henderson is also Co-Inventor of the EV1 Peptide™. He directs Evolv’s scientific and clinical programs, translating molecular biology into human trials and consumer health applications. His leadership ensures that Evolv’s biomimetic innovations are developed with the same rigor as pharmaceutical research while remaining accessible outside of the clinic.
Kwang-Chul Kwon, Ph.D., is an internationally recognized molecular biologist with over 15 years of experience engineering plants, algae, yeast, and cyanobacteria as bioreactor platforms for therapeutic proteins. He has authored more than 30 peer-reviewed publications, cited over 1,200 times in the scientific literature, with appearances in Plant Biotechnology Journal, Molecular Therapy, and Biomaterials. His breakthroughs, from codon-optimization algorithms to marker-free chloroplast transformation systems, have been cited as defining advances in oral biologics.
Dr. Kwon’s contributions have earned him major recognition, including the American Heart Association’s Top Basic Science Paper Award and the Nutreco Feed Tech Challenge. He previously held senior scientific leadership roles at the University of Pennsylvania and served as Chief Scientific Officer at multiple biotechnology firms.
As Co-Founder and CTO of Evolv, Dr. Kwon is also Co-Inventor of the EV1 Peptide™. He architected Evolv’s edible bioreactor platform and directs its expansion into new biomimetic peptides, ensuring scalability, safety, and scientific credibility at every step.
Evolv was founded on the principle that biotechnology should meet the highest standards of evidence, even when applied to consumer health. With Dr. Henderson and Dr. Kwon as its scientific leaders, Evolv represents a new model: accessibility grounded in molecular rigor.
The EV1 Peptide™ is more than an ingredient. It is the product of careers spent advancing molecular biology, expression platforms, and translational science, brought together to create a new era of biomimetic innovation.
EVOLV GLP-1
Studies
At Evolv, science is not an afterthought. It is the foundation. The EV1 Peptide™, the first biomimetic GLP-1 designed for oral delivery, emerged from decades of research in molecular biology, expression systems, and peptide engineering.
EVOLV GLP-1
Here’s the big question we hear all the time: “Can a simple daily tablet really deliver the power of GLP-1?” With Evolv, the answer is yes.
EVOLV GLP-1
GLP-1 BENEFITS
At Evolv, we believe the key to metabolic health isn’t about overriding your body. It’s about supporting the hormones and systems that were already designed to keep you healthy.
